• Opportunity for Expansion into NHS and EU Government Projects Following Supply to Oxford
Oxford University Hospitals, in the UK, has officially adopted Coreline Soft's proprietary AI software, ‘AVIEW LCS Plus’. CEO Kim Jin-Kook announced recently that Coreline Soft will now supply its AI products to Oxford University, one of the world’s leading academic institutions, after securing contracts with Bayer in Germany and registering for public procurement in France.
Coreline Soft disclosed on May 20th that Oxford University Hospitals officially adopted its proprietary AI software, ‘AVIEW LCS Plus. Oxford University is recognized as the world’s top university according to the Times Higher Education (THE) global university rankings, holding the number one position for nine consecutive years up to this year, and possesses unparalleled research capability and influence. Oxford University Hospitals is regarded as the most influential medical institution in Europe in terms of public healthcare, clinical trials, and technology adoption. The company explained that this supply is expected to significantly expand prospects for future projects led by governments around the world and opportunities with global corporations worldwide.
Notably, this contract signifies a major recognition of Coreline Soft’s medical AI technology and products by Oxford University, which boasts a prestigious international reputation in the medical field. Following validation through international academic journals demonstrating that its AI technology surpasses products from the world’s top-ranked medical imaging diagnostic companies, demand for supply requests from global corporations and medical institutions has been rapidly increasing.
Under the terms of the contract, Oxford University Hospitals will conduct preliminary research to verify AVIEW LCS Plus’s performance using lung cancer screening imaging data from the UK, as well as evaluate its potential for early detection of lung and thoracic diseases. The UK operates a public health system centered around the National Health Service (NHS), which is actively promoting the adoption of AI-based early diagnosis systems.
CEO Kim stated, “The supply to Oxford University Hospitals demonstrates that our AI technology is recognized by one of the world’s top academic institutions,” adding, “As demand for AI-driven lung cancer screening solutions is rapidly increasing, we will continue to expand collaborations with healthcare and research institutions, as well as governments across Europe, to accelerate orders for AI-based early diagnosis projects.”
Coreline Soft is already involved in government-led lung cancer screening projects in key European countries such as Germany and France. It recently achieved a 60% market share among the top ten hospitals in Germany. The company plans to strengthen its partnerships with institutions under the UK’s National Health Service to secure further achievements, starting with Oxford University Hospitals.
